19th January 2015
Minister for Life Sciences visits Roche Diagnostics UK and Ireland Head Office in Burgess Hill
George Freeman, Minister for Life Sciences, visited the head office of Roche Diagnostics in Burgess Hill today. Managing Director, Christopher Parker, and his team gave Mr Freeman an introduction to the company and broad range of in vitro diagnostic tests in areas such as womens’ health, cancer, HIV and cardiac health.
Life Sciences Minister George Freeman said:
“The Government is committed to embracing new medical technologies in the NHS - working with global life science companies like Roche Diagnostics to bring NHS patients access to 21st Century medical innovations. Fast, precise and advanced diagnostics such as those being introduced from Burgess Hill are key to modern healthcare”
Speaking after the visit, Christopher Parker said, “It was a pleasure to welcome Mr Freeman and to hear more about his plans. New tests and medical technologies are moving at a rapid pace and we help to ensure UK families have the very best choices available to them.”
Notes to Editors
- Roche Diagnostics Limited in the UK & Ireland is led by Managing Director Christopher Parker. The Company, which is headquartered in Burgess Hill, West Sussex, with a distribution centre at Newhaven, East Sussex, serves customers throughout the UK and the Republic of Ireland.
- George Freeman is the first UK Minister for Life Sciences. Prior to being elected to Parliament in 2010 George Freeman had a 15 year career in the Life Science sector, setting up and raising finance for, high-growth start-up biomedical companies. After 3 years as Life Science Adviser to the UK government, in July 2014 he was appointed by the Prime Minister as the first UK Minister for Life Sciences.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century.
Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com
All trademarks used or mentioned in this release are protected by law.